TY - JOUR
T1 - Myeloperoxidase is Independently Associated with Incident Heart Failure in Patients with Coronary Artery Disease and Kidney Disease
AU - Janus, Scott E.
AU - Hajjari, Jamal
AU - Chami, Tarek
AU - Karnib, Mohamad
AU - Al-Kindi, Sadeer G.
AU - Rashid, Imran
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/11
Y1 - 2022/11
N2 - Chronic kidney disease (CKD) is associated with high cardiovascular risk and mortality. Myeloperoxidase (MPO) has been linked to adverse events in patients with mild-moderate CKD. We sought to investigate whether MPO levels are associated with adverse outcomes in patients with CKD. We studied participants with mild to moderate CKD in the prospective chronic renal insufficiency cohort (CRIC). We followed patients for incident heart failure (HF), death, and composite outcome (myocardial infarction, incident peripheral arterial disease, cerebrovascular accident and death). A total of 3872 patients were included (2702 without CVD, 1170 with CVD). After multiple adjustments, doubling of MPO in patients with prior CAD was associated with risk of HF (HR 1.15 [1.01-1.30], P = 0.032) and mortality (HR 1.16 [1.05-1.30], P = 0.005), and composite outcome of MI, PAD, CVA and death (HR 1.12 [1.01-1.25], P = 0.031). In this cohort of patients with mild to moderate CKD and CAD, MPO levels are independently associated with incident HF, all-cause mortality, and a composite outcome.
AB - Chronic kidney disease (CKD) is associated with high cardiovascular risk and mortality. Myeloperoxidase (MPO) has been linked to adverse events in patients with mild-moderate CKD. We sought to investigate whether MPO levels are associated with adverse outcomes in patients with CKD. We studied participants with mild to moderate CKD in the prospective chronic renal insufficiency cohort (CRIC). We followed patients for incident heart failure (HF), death, and composite outcome (myocardial infarction, incident peripheral arterial disease, cerebrovascular accident and death). A total of 3872 patients were included (2702 without CVD, 1170 with CVD). After multiple adjustments, doubling of MPO in patients with prior CAD was associated with risk of HF (HR 1.15 [1.01-1.30], P = 0.032) and mortality (HR 1.16 [1.05-1.30], P = 0.005), and composite outcome of MI, PAD, CVA and death (HR 1.12 [1.01-1.25], P = 0.031). In this cohort of patients with mild to moderate CKD and CAD, MPO levels are independently associated with incident HF, all-cause mortality, and a composite outcome.
UR - http://www.scopus.com/inward/record.url?scp=85122929738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122929738&partnerID=8YFLogxK
U2 - 10.1016/j.cpcardiol.2021.101080
DO - 10.1016/j.cpcardiol.2021.101080
M3 - Review article
C2 - 34910944
AN - SCOPUS:85122929738
SN - 0146-2806
VL - 47
JO - Current Problems in Cardiology
JF - Current Problems in Cardiology
IS - 11
M1 - 101080
ER -